CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
Aug. 31, 2026	Aug. 31, 2025
Cash flows from operating activities
Net income (loss)	$ 373,098	$ (186,236)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	6,590	6,620
Stock-based compensation	31,569	28,879
Net accretion of discount on marketable securities	(4,475)	(8,455)
Loss on disposal of property and equipment	160	0
Amortization of operating lease right-of-use assets	4,651	7,605
Changes in operating assets and liabilities:
Accounts receivable	(20,000)	0
Prepaid expenses and other assets	(12,013)	(4,945)
Accounts payable	22,022	(3,655)
Deferred revenue	(8,203)	(23,403)
Operating lease liabilities	(1,161)	(4,311)
Deferred collaboration funding	45,609	0
Accrued expenses and other current liabilities	9,297	6,268
Net cash provided by (used in) operating activities	447,144	(181,633)
Cash flows from investing activities
Purchases of marketable securities	(430,005)	(281,350)
Maturities of marketable securities	435,130	437,728
Purchases of property and equipment	(4,373)	(8,871)
Net cash provided by investing activities	752	147,507
Cash flows from financing activities
Proceeds from exercise of stock options	4,461	405
Proceeds from issuance of common stock under employee stock purchase plan	2,735	2,229
Proceeds from issuances of common stock in “at the market” financing, net of issuance costs	18,004	0
Net cash provided by financing activities	25,200	2,634
Net increase (decrease) in cash, cash equivalents and restricted cash	473,096	(31,492)
Cash, cash equivalents and restricted cash at beginning of period	247,928	110,898
Cash, cash equivalents and restricted cash at end of period	721,024	79,406
Supplemental disclosures of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities	455	2,120
Right-of-use assets recognized in exchange for lease obligations	2,765	32,494
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	720,242	78,438
Restricted cash	782	968
Total cash, cash equivalents and restricted cash	$ 721,024	$ 79,406

Increase (Decrease) in Deferred Collaboration Funding

No definition available.

Name:	nrix_IncreaseDecreaseInDeferredCollaborationFunding
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.